

CNMV
Edison, 4
28006 Madrid

Barcelona (Spain) January 15, 2025

OTHER RELEVANT INFORMATION

In accordance with the provisions set forth in Article 227 of Law 6/2023, of March 17, on Securities Markets and Investment Services, **LABORATORIO REIG JOFRE SA** ("Reig Jofre" or "the Company"), submits hereafter press release regarding the announcement of the appointment of Teresa Pérez de Prada as the new Director of its Toledo plant.

Yours faithfully,

Adolf Rousaud
Secretary non director of the Board of Directors
Laboratorio Reig Jofre SA

TOLEDO, January 15, 2025

REIG JOFRE appoints Teresa Pérez de Prada as Director of its antibiotic development and production plant in Toledo



- REIG JOFRE strengthens its leadership in betalactam antibiotic manufacturing with the appointment of Teresa Pérez de Prada as Director of its strategic plant in Toledo
- This appointment reinforces the company's commitment to innovation, talent, and the universalization of essential health solutions on a global scale

REIG JOFRE, (BME:**RJF**), a pharmaceutical company listed on the Spanish Stock Exchange, today announced the appointment of **Teresa Pérez de Prada** as the new **Director of its Toledo plant**. This appointment consolidates the company's position as a leader in high-quality antibiotic manufacturing, particularly in the field of betalactam antibiotics, and underscores its mission to universalize global access to essential health solutions.

With over 17 years of experience in the pharmaceutical industry, Teresa Pérez de Prada brings an exceptional academic and professional background. She holds a Ph.D. in Biological Sciences and a Master's in Immunology from the Complutense University of Madrid. In addition, she has led key Operations and Production areas at international companies such as Takeda and Lonza Biologics. This appointment brings a unique combination of leadership, technical expertise, and a strong commitment to innovation.

The Toledo plant plays a critical role in Reig Jofre's global strategy. As one of the leading production centers for betalactam antibiotics in Europe, this facility combines operational excellence, advanced technology, and a firm commitment to sustainability. In a rapidly transforming healthcare landscape, REIG JOFRE continues to prioritize talent and collaboration as essential pillars to ensure the sustainability of healthcare systems and drive global innovation.

With the arrival of Teresa Pérez de Prada, REIG JOFRE reaffirms its vision of building a collaborative ecosystem that integrates talent, technology, and purpose, strengthening its position as a leader in essential pharmaceutical solutions for global well-being.

About REIG JOFRE

REIG JOFRE is a pharmaceutical company founded with the firm conviction of universalizing healthcare, bringing both basic and innovative solutions to people worldwide. To deliver pioneering and high-impact solutions, the company employs cutting-edge production technology, collaborates continuously with innovative companies, researchers, and startups, and invests heavily in R&D&I. Since 1929, it has been developing, manufacturing, and marketing essential pharmaceutical products under three major areas: Pharmaceutical Technologies, Specialty Pharmacare, and Consumer Healthcare. REIG JOFRE operates four development and production centers across Europe, with dedicated teams in Spain, France, Portugal, Belgium, Sweden, the United Kingdom, and Poland, and an extensive commercial network in over 70 countries. With more than 1,300 employees, the company closed in 2023 with a turnover of €316M (+17% vs. 2022) and an EBITDA of €35M (+15% vs. 2022). REIG JOFRE is listed on the Spanish Stock Exchange under the ticker RJF.

For more information

Inma Santa-Pau - Director of Communication and Public Relations - isantapau@reigjofre.com

www.reigjofre.com